Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03490344 · ClinicalTrials.gov registry record · Phase 2
Short Course Daratumumab in Patients With Multiple Myeloma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03490344: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03490344 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03490344, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of short course Daratumumab in combination with lenalidomide and to find out what effects, if any, short course Daratumumab in combination with lenalidomide has on people and their risk of multiple myeloma. The study is also designed to test the amount of remaining myeloma cells in your body after treatment with daratumumab which is known as minimal residual disease (MRD).
Interventions
- DRUG Lenalidomide
- DRUG Daratumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2023-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03490344
The ClinicalTrials.gov registry entry for NCT03490344 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT03490344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03490344 about?
NCT03490344 is a clinical study titled "Short Course Daratumumab in Patients With Multiple Myeloma". The purpose of this study is to test the safety of short course Daratumumab in combination with lenalidomide and to find out what effects, if any, short course Daratumumab in combination with lenalidomide has on people and their risk of multiple myeloma. The study is also designed to test the amount...
What is the current status of trial NCT03490344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-05-03. Estimated completion is 2023-03-23.
What interventions are being tested in trial NCT03490344?
The interventions under investigation include: Lenalidomide (DRUG), Daratumumab (DRUG).
Who is sponsoring clinical trial NCT03490344?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.